Pfizer and Roche among sponsors of HTA data-sharing initiative

10 January 2018

Pharma giants Pfizer (NYSE: PFE) and Roche (ROG: SIX) are two of seven sponsors announced for a pioneering project to generate, align and share disease-level data across an entire condition for health technology assessments (HTA).

The collaboration, known as HERCULES, will focus on medicines for Duchenne muscular dystrophy (DMD) with the aim of improving the chances of medicines for rare and orphan diseases to receive positive decisions from the UK’s National Institute for Health and Care Excellence, France’s Haute Autorité de Santé and other HTA bodies.

"HERCULES has the potential to transform HTA submissions in DMD and other rare diseases"

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK